BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 07, 2005
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/4 cls
Actelion (SWX:ATLN) Lehman Sam Williams Price target Overweight -2% CHF 125.0
Williams raised his target to CHF160 from CHF140 in anticipation of the 4Q release of Tracleer Phase II/III data in pulmonary fibrosis. He also lowered his FY05 and FY06 EPS estimates to CHF3.17 from CHF5.12 and to CHF4.24 from CHF5.59, respectively, to reflect increased investment in Tracleer programs and marketing.
Biogen Idec (BIIB) Deutsche Bank Jennifer Chao Downgrade Sell (from buy) -44% $37.53
Lazard Joel Sendek Downgrade Hold (from buy)
Morgan Stanley Steven Harr Price...

Read the full 651 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >